Metis Global Partners LLC Sells 3,304 Shares of AbbVie Inc. $ABBV

Metis Global Partners LLC lessened its stake in AbbVie Inc. (NYSE:ABBV) by 3.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 93,982 shares of the company’s stock after selling 3,304 shares during the quarter. AbbVie comprises about 0.5% of Metis Global Partners LLC’s investment portfolio, making the stock its 27th largest holding. Metis Global Partners LLC’s holdings in AbbVie were worth $21,474,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Eclectic Associates Inc. ADV increased its holdings in AbbVie by 0.8% in the fourth quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock valued at $1,337,000 after purchasing an additional 45 shares during the last quarter. Weil Company Inc. increased its holdings in AbbVie by 2.3% in the third quarter. Weil Company Inc. now owns 2,026 shares of the company’s stock valued at $469,000 after purchasing an additional 46 shares during the last quarter. Hardin Capital Partners LLC increased its holdings in AbbVie by 1.4% in the fourth quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company’s stock valued at $759,000 after purchasing an additional 46 shares during the last quarter. Dogwood Wealth Management LLC increased its holdings in AbbVie by 10.8% in the fourth quarter. Dogwood Wealth Management LLC now owns 473 shares of the company’s stock valued at $108,000 after purchasing an additional 46 shares during the last quarter. Finally, Quantum Private Wealth LLC increased its holdings in shares of AbbVie by 2.0% in the fourth quarter. Quantum Private Wealth LLC now owns 2,376 shares of the company’s stock worth $543,000 after acquiring an additional 46 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

NYSE:ABBV opened at $225.16 on Thursday. The company has a market cap of $397.82 billion, a PE ratio of 110.92, a PEG ratio of 0.69 and a beta of 0.32. AbbVie Inc. has a 52-week low of $181.73 and a 52-week high of $244.81. The stock has a 50-day simple moving average of $210.64 and a 200 day simple moving average of $219.09.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The business had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.AbbVie’s quarterly revenue was up 12.4% on a year-over-year basis. During the same period last year, the company earned $2.46 earnings per share. On average, research analysts predict that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ABBV has been the subject of several recent analyst reports. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday. Royal Bank Of Canada initiated coverage on AbbVie in a report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price target for the company. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Piper Sandler increased their price target on AbbVie from $294.00 to $298.00 and gave the stock an “overweight” rating in a report on Thursday, May 14th. Finally, Guggenheim restated a “buy” rating and issued a $249.00 price target on shares of AbbVie in a report on Friday, May 1st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $253.43.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s migraine drug was cleared for use in migraine attacks on the NHS, a sign of broader adoption potential that could support future sales growth. AbbVie’s migraine drug cleared for migraine attacks on NHS
• Positive Sentiment: Allergan Aesthetics, an AbbVie company, highlighted new consumer research in its aesthetics business, reinforcing ongoing brand visibility and interest in its aesthetics portfolio. Allergan Aesthetics Releases ‘The Aesthetics Evolution: What Consumers Really Want’
• Neutral Sentiment: AbbVie presented at Goldman Sachs’ healthcare conference, which typically provides investors with updates on strategy and pipeline but did not include a major new catalyst in the headline. AbbVie Inc. (ABBV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: AbbVie was mentioned in “final trades” and “below fair value”/discount-stock roundups, which may keep valuation-focused investors interested but are not company-specific operational news. Final trades: AbbVie, Morgan Stanley, Shake Shack and the CBOE
• Negative Sentiment: AbbVie received a Complete Response Letter from the FDA for TrenibotE, its fast-acting neurotoxin candidate. The agency cited manufacturing-related issues and raised no safety or efficacy concerns, but the delay still pushes back a potential new product launch. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE
• Negative Sentiment: AbbVie also terminated its deal with I-Mab to develop a cancer drug, removing a potential pipeline opportunity and signaling a setback in its oncology collaboration strategy. AbbVie terminates deal with I-Mab to develop cancer drug

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.